1. Executive Summary
The Machado-Joseph Disease (MJD), or Spinocerebellar Ataxia Type 3 (SCA3), treatment market is currently driven by symptomatic management but is on the cusp of significant transformation due to a robust pipeline of disease-modifying therapies (DMTs). MJD is the most common autosomal dominant ataxia, caused by a CAG repeat expansion in the ATXN3 gene.
The global Machado...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Portuguese (Brazil)
Greek